InflaRx to Report Second Quarter 2024 Results on August 8, 2024
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, has announced it will release its second quarter 2024 financial and operating results on August 8, 2024, before the market opens. No conference call is scheduled for this report.
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor C5aR. Their lead product candidate, vilobelimab, is an intravenously delivered anti-C5a monoclonal antibody that has shown promising clinical activity in various indications. The company is also developing INF904, an oral small molecule inhibitor of the C5a receptor.
Founded in 2007, InflaRx has offices in Jena and Munich, Germany, and Ann Arbor, MI, USA.
InflaRx N.V. (Nasdaq: IFRX), una società biofarmaceutica che si concentra su terapeutiche anti-infiammatorie, ha annunciato che rilascerà i suoi risultati finanziari e operativi del secondo trimestre 2024 il 8 agosto 2024, prima dell'apertura del mercato. Non è prevista alcuna conferenza telefonica per questo resoconto.
InflaRx si specializza nello sviluppo di inibitori del fattore di attivazione del complemento C5a e del suo recettore C5aR. Il loro principale candidato prodotto, vilobelimab, è un anticorpo monoclonale anti-C5a somministrato per via endovenosa che ha mostrato un'attività clinica promettente in varie indicazioni. L'azienda sta anche sviluppando INF904, un inibitore orale di piccole molecole del recettore C5a.
Fondata nel 2007, InflaRx ha uffici a Jena e Monaco, in Germania, e ad Ann Arbor, MI, USA.
InflaRx N.V. (Nasdaq: IFRX), una compañía biofarmacéutica enfocada en terapias antiinflamatorias, ha anunciado que publicará sus resultados financieros y operativos del segundo trimestre de 2024 el 8 de agosto de 2024, antes de la apertura del mercado. No se ha programado ninguna conferencia telefónica para este informe.
InflaRx se especializa en el desarrollo de inhibidores del factor de activación del complemento C5a y su receptor C5aR. Su principal candidato a producto, vilobelimab, es un anticuerpo monoclonal anti-C5a administrado por vía intravenosa que ha mostrado una actividad clínica prometedora en varias indicaciones. La compañía también está desarrollando INF904, un inhibidor oral de pequeñas moléculas del receptor C5a.
Fundada en 2007, InflaRx tiene oficinas en Jena y Múnich, Alemania, y Ann Arbor, MI, EE. UU.
인플라Rx N.V. (Nasdaq: IFRX)는 항염 치료제에 중점을 둔 생명공학 회사로, 2024년 2분기 재무 및 운영 결과를 2024년 8월 8일에 시장 개장 전에 발표할 것이라고 발표했습니다. 이 보고서에 대한 컨퍼런스 콜은 예정되어 있지 않습니다.
인플라Rx는 보Complement 활성화 인자 C5a 및 그 수용체 C5aR의 억제제를 개발하는 데 전문화되어 있습니다. 그들의 주요 제품 후보인 vilobelimab는 정맥 주사로 투여되는 항-C5a 단클론 항체로, 여러 적응증에서 유망한 임상 활동을 보여주었습니다. 이 회사는 또한 C5a 수용체의 구강 소분자 억제제인 INF904를 개발하고 있습니다.
2007년에 설립된 인플라Rx는 독일 예나, 뮌헨 및 미국 미시간주 앤아버에 사무소를 두고 있습니다.
InflaRx N.V. (Nasdaq: IFRX), une société biopharmaceutique spécialisée dans les traitements anti-inflammatoires, a annoncé qu'elle publiera ses résultats financiers et opérationnels du deuxième trimestre 2024 le 8 août 2024, avant l'ouverture du marché. Aucune conférence téléphonique n'est prévue pour ce rapport.
InflaRx se spécialise dans le développement d'inhibiteurs du facteur d'activation du complément C5a et de son récepteur C5aR. Leur produit candidat principal, le vilobelimab, est un anticorps monoclonal anti-C5a administré par voie intraveineuse qui a montré une activité clinique prometteuse dans diverses indications. La société développe également INF904, un inhibiteur oral de petites molécules du récepteur C5a.
Fondée en 2007, InflaRx dispose de bureaux à Jena et Munich, en Allemagne, et à Ann Arbor, MI, aux États-Unis.
InflaRx N.V. (Nasdaq: IFRX), ein biopharmazeutisches Unternehmen, das sich auf entzündungshemmende Therapeutika konzentriert, hat bekannt gegeben, dass es seine Finanz- und Betriebsergebnisse für das zweite Quartal 2024 am 8. August 2024 vor Markteröffnung veröffentlichen wird. Es ist keine Telefonkonferenz für diesen Bericht geplant.
InflaRx spezialisiert sich auf die Entwicklung von Inhibitoren des Komplementaktivierungsfaktors C5a und dessen Rezeptor C5aR. Ihr Hauptproduktkandidat, vilobelimab, ist ein intravenös verabreichter anti-C5a monoklonaler Antikörper, der in verschiedenen Indikationen vielversprechende klinische Aktivitäten gezeigt hat. Das Unternehmen entwickelt auch INF904, einen oralen kleinen Molekülinhibitor des C5a-Rezeptors.
Gegründet im Jahr 2007, hat InflaRx Büros in Jena und München, Deutschland, sowie in Ann Arbor, MI, USA.
- Scheduled release of Q2 2024 financial results, indicating transparency and regular reporting
- Ongoing development of vilobelimab, a potential first-in-class anti-C5a monoclonal antibody
- Diversified pipeline with INF904, an oral C5a receptor inhibitor in development
- None.
JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its second quarter 2024 financial and operating results on August 8, 2024, before the market opens. No conference call is planned.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When will InflaRx (IFRX) report its Q2 2024 financial results?
What is InflaRx's (IFRX) lead product candidate?
What other product is InflaRx (IFRX) developing besides vilobelimab?
What is the focus of InflaRx's (IFRX) drug development?
